Selection of proton pump inhibitors for formulary inclusion: Making decisions based on appropriate criteria

Stephen W. Nissen, Keith M. Olsen

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

To accurately assess any therapeutic class or specific agent for inclusion in the hospital formulary, a consistent evidence-based review process should be followed. Utilization of any therapeutic class, including the proton pump inhibitors, is more efficient if a single agent is used throughout the healthcare system. The lack of evidence supporting intravenous proton pump inhibitor therapy in stress-related mucosal damage and no comparative data in non-variceal upper gastrointestinal bleeding allows interchange of all agents more readily. Although many factors need consideration, the ideal proton pump inhibitor should be available orally and intravenously, and be prepared easily for administration to patients unable to swallow capsules or tablets. Using these criteria, the hospital system may be able to leverage the best possible cost for selection of a proton pump inhibitor for their formulary.

Original languageEnglish (US)
Pages (from-to)289-298
Number of pages10
JournalDisease Management and Health Outcomes
Volume15
Issue number5
DOIs
StatePublished - Jan 1 2007

Fingerprint

Formularies
Proton Pump Inhibitors
Decision Making
Hospital Formularies
Deglutition
Tablets
Capsules
Therapeutics
Hemorrhage
Delivery of Health Care
Costs and Cost Analysis

Keywords

  • Esomeprazole, therapeutic use
  • Formularies
  • Intravenous
  • Lansoprazole, therapeutic use
  • Omeprazole, therapeutic use
  • Oral
  • Pantoprazole, therapeutic use
  • Proton pump inhibitors, therapeutic use
  • Rabeprazole, therapeutic use
  • Routes of administration

ASJC Scopus subject areas

  • Leadership and Management
  • Nursing(all)
  • Health Policy

Cite this

Selection of proton pump inhibitors for formulary inclusion : Making decisions based on appropriate criteria. / Nissen, Stephen W.; Olsen, Keith M.

In: Disease Management and Health Outcomes, Vol. 15, No. 5, 01.01.2007, p. 289-298.

Research output: Contribution to journalReview article

@article{b053e155f3104ebeaee61c4868c26bb6,
title = "Selection of proton pump inhibitors for formulary inclusion: Making decisions based on appropriate criteria",
abstract = "To accurately assess any therapeutic class or specific agent for inclusion in the hospital formulary, a consistent evidence-based review process should be followed. Utilization of any therapeutic class, including the proton pump inhibitors, is more efficient if a single agent is used throughout the healthcare system. The lack of evidence supporting intravenous proton pump inhibitor therapy in stress-related mucosal damage and no comparative data in non-variceal upper gastrointestinal bleeding allows interchange of all agents more readily. Although many factors need consideration, the ideal proton pump inhibitor should be available orally and intravenously, and be prepared easily for administration to patients unable to swallow capsules or tablets. Using these criteria, the hospital system may be able to leverage the best possible cost for selection of a proton pump inhibitor for their formulary.",
keywords = "Esomeprazole, therapeutic use, Formularies, Intravenous, Lansoprazole, therapeutic use, Omeprazole, therapeutic use, Oral, Pantoprazole, therapeutic use, Proton pump inhibitors, therapeutic use, Rabeprazole, therapeutic use, Routes of administration",
author = "Nissen, {Stephen W.} and Olsen, {Keith M.}",
year = "2007",
month = "1",
day = "1",
doi = "10.2165/00115677-200715050-00003",
language = "English (US)",
volume = "15",
pages = "289--298",
journal = "Disease Management and Health Outcomes",
issn = "1173-8790",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Selection of proton pump inhibitors for formulary inclusion

T2 - Making decisions based on appropriate criteria

AU - Nissen, Stephen W.

AU - Olsen, Keith M.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - To accurately assess any therapeutic class or specific agent for inclusion in the hospital formulary, a consistent evidence-based review process should be followed. Utilization of any therapeutic class, including the proton pump inhibitors, is more efficient if a single agent is used throughout the healthcare system. The lack of evidence supporting intravenous proton pump inhibitor therapy in stress-related mucosal damage and no comparative data in non-variceal upper gastrointestinal bleeding allows interchange of all agents more readily. Although many factors need consideration, the ideal proton pump inhibitor should be available orally and intravenously, and be prepared easily for administration to patients unable to swallow capsules or tablets. Using these criteria, the hospital system may be able to leverage the best possible cost for selection of a proton pump inhibitor for their formulary.

AB - To accurately assess any therapeutic class or specific agent for inclusion in the hospital formulary, a consistent evidence-based review process should be followed. Utilization of any therapeutic class, including the proton pump inhibitors, is more efficient if a single agent is used throughout the healthcare system. The lack of evidence supporting intravenous proton pump inhibitor therapy in stress-related mucosal damage and no comparative data in non-variceal upper gastrointestinal bleeding allows interchange of all agents more readily. Although many factors need consideration, the ideal proton pump inhibitor should be available orally and intravenously, and be prepared easily for administration to patients unable to swallow capsules or tablets. Using these criteria, the hospital system may be able to leverage the best possible cost for selection of a proton pump inhibitor for their formulary.

KW - Esomeprazole, therapeutic use

KW - Formularies

KW - Intravenous

KW - Lansoprazole, therapeutic use

KW - Omeprazole, therapeutic use

KW - Oral

KW - Pantoprazole, therapeutic use

KW - Proton pump inhibitors, therapeutic use

KW - Rabeprazole, therapeutic use

KW - Routes of administration

UR - http://www.scopus.com/inward/record.url?scp=35348830578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348830578&partnerID=8YFLogxK

U2 - 10.2165/00115677-200715050-00003

DO - 10.2165/00115677-200715050-00003

M3 - Review article

AN - SCOPUS:35348830578

VL - 15

SP - 289

EP - 298

JO - Disease Management and Health Outcomes

JF - Disease Management and Health Outcomes

SN - 1173-8790

IS - 5

ER -